GVR Report cover Restriction Endonucleases Products Market Size, Share & Trends Report

Restriction Endonucleases Products Market Size, Share & Trends Analysis Report By Application, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2025

  • Report ID: GVR1269
  • Number of Pages: 0
  • Format: Electronic (PDF)

Restriction endonucleases product market is expected to grow during the forecast period owing to the increasing expenditure on research & development by biotechnology and pharmaceutical companies. Increasing funding in genomics and life science, an increasing number of geriatric population, and the growing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer are the vital growth propellers for this market. Furthermore, newly evolved techniques such as DNA sequencing and gene expression is expected to fuel market growth. DNA sequencing is the process through which nucleotides are extracted in a precise order. This process further drives the growth of molecular biology enzymes, kits & reagents market. As the demand for healthcare facilities is growing in both developed and developing countries, this is directly leading to an increase in demand for clinical information systems.

Restriction endonucleases product market is segmented on the basis of application and end-use. On the basis of the application market is divided into PCR (polymerase chain reaction), epigenetics, restriction fragment length polymorphism (RFLP), cloning, sequencing, and restriction digestion. Among these PCR application held the largest market share in 2013. PCR is a process through which multiple copies of DNA are generated from a particular DNA sequence, thereby helps in the diagnosis of hereditary diseases, identifies genetic fingerprints and detects various infectious diseases. On the basis of end-use, the market is divided into hospitals, academic research institutes, pharmaceutical, diagnostic centers, biotechnology companies, clinics, and other end users.

Geographically, the restriction endonucleases product market is divided into North America, Europe, Asia Pacific, and RoW. North America is dominating the whole region as of 2013, followed by Europe. The reason for its dominance is due to the presence of strong research and development in biotechnology, rising contract research outsourcing, and increasing funds for genomic and life science. Asia Pacific market is expected to show lucrative CAGR during the forecast period owing to the rapidly developing healthcare infrastructure, improving, patient awareness, and various government initiatives.

The major players of restriction endonucleases products market are Agilent Technologies, Inc., Affymetrix, Inc., Illumina, Inc., Enzymatics, Inc., QIAGEN N.V., New England Biolabs, Inc., Sigma-Aldrich Co. LLC., Roche, Ltd., Thermo Fisher Scientific, Inc. and Takara Bio, Inc. The market players are involved in developing novel technologies to meet the requirements of users. These companies are also involved in various mergers & acquisitions, to maintain substantial market share. 

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.